121 results on '"Budree, Shrish"'
Search Results
2. Influence of Maternal Childhood Trauma on Perinatal Depression, Observed Mother-Infant Interactions, and Child Growth
3. Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study
4. Pilot study of autologous fecal microbiota transplants in nursing home residents: Feasibility and safety
5. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study
6. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial
7. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection
8. Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose
9. Gut microbial dysbiosis in individuals with Sjögren’s syndrome
10. Assessing the Microbiome—Current and Future Technologies and Applications
11. S146 Evaluation of Engraftment and Diversity Following Open-Label Administration of CP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection, in the PRISM-EXT Trial
12. Correction to: Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future
13. Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future
14. Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study
15. Correction to: Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose
16. Tu1519: CP101, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A COMBINED ANALYSIS OF THE PRISM3 (RANDOMIZED PLACEBO-CONTROLLED) AND PRISM-EXT (OPEN-LABEL) TRIALS
17. 583: CP101, AN INVESTIGATIONAL ORALLY ADMINISTERED MICROBIOME THERAPEUTIC, WAS EFFECTIVE FOR PREVENTION OF RECURRENT C. DIFFICILE INFECTION: RESULTS FROM OPEN-LABEL PRISM-EXT TRIAL
18. S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection
19. S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial
20. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study
21. Framework for rational donor selection in fecal microbiota transplant clinical trials
22. Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation
23. Gut Microbial Dysbiosis in Individuals with Sjögren’s Syndrome
24. Global disparities in faecal microbiota transplantation research
25. Donor Screening for Fecal Microbiota Transplantation
26. Framework for rational donor selection in fecal microbiota transplant clinical trials
27. Gut microbial dysbiosis in individuals with Sjögren’s disease
28. 1101 – Fmt with Or Without Antibiotic Pretreatment in Patients with Ibs-D: Results of a Double-Blind, Randomized, Placebo-Controlled Trial
29. 512 – Donor Health Screening for Fecal Microbiota Transplantation: Prospective Evaluation of 15,317 Candidate Donors
30. Su1951 – Global Disparities and New Indications in Fecal Microbiota Transplantation Research: A Survey and Systematic Review of Clinical Trials Around the World
31. Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose
32. 618. Do Clinical Factors Affect Microbial Engraftment After Fecal Microbiota Transplantation in Recurrent Clostridium difficile Infection?
33. 742 - A Double-Blind, Randomized, Placebo-Controlled Trial of Fecal Microbiota Transplantation Capsules (FMTC) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
34. 88 - Does the Donor Matter? Microbiome Sequencing to Evaluate Lower Donor Efficacy in Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection
35. Tu1882 - Fecal Microbiota Transplantation Improves Gastrointestinal Graft-Versus-Host Disease and Restores the Microbiome: A Pediatric Experience
36. 1010 - Scaling Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficle Infection in the United States: A Geospatial Time-Series Analysis from 2013 to 2017
37. HIV-exposure, early life feeding practices and delivery mode impacts on faecal bacterial profiles in a South African birth cohort
38. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases
39. Donor Stool Processing Time: The Effect on the Intestinal Microbiome and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection
40. The Association of Donor Stool Consistency by Bristol Stool Scale on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection
41. Pediatric Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in the United States and the Impact of Stool Banks: A Geospatial Analysis
42. Do Specific Bacteria Drive Clinical Cure in Fecal Microbiota Transplantation for Clostridium Difficile Infection?: Clinical, Microbial and Metabolomic Characterization of Universal FMT Donors
43. The Association of Stool Donor Diet on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection
44. Infant feeding practices in a South African birth cohort-A longitudinal study
45. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases.
46. Tu1918 - Donor Stool Processing Time: The Effect on the Intestinal Microbiome and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection
47. Tu1066 - Pediatric Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in the United States and the Impact of Stool Banks: A Geospatial Analysis
48. Su2018 - The Association of Stool Donor Diet on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection
49. Su2017 - The Association of Donor Stool Consistency by Bristol Stool Scale on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection
50. Sa1793 - Do Specific Bacteria Drive Clinical Cure in Fecal Microbiota Transplantation for Clostridium Difficile Infection?: Clinical, Microbial and Metabolomic Characterization of Universal FMT Donors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.